One of the main barriers to medication adherence among diabetics is the painful, constant administration of insulin using a needle and syringes. Moreover, subcutaneous insulin administration has long been admonished for its slow onset of action. People living with this chronic condition need a convenient and efficient method of administering this crucial hormone. Biopharmaceutical company Aerami Therapeutics (formerly Dance Biopharm) may have a solution that changes the way insulin is delivered.